Nanoparticle Orientation to Control RNA Loading and Ligand Display on Extracellular Vesicles for Cancer Regression

Nanotechnology offers many benefits, and here we report an advantage of applying RNA nanotechnology for directional control. The orientation of arrow-shaped RNA was altered to control ligand display on extracellular vesicle membranes for specific cell targeting, or to regulate intracellular trafficking of small interfering RNA (siRNA) or microRNA (miRNA). Placing membrane-anchoring cholesterol at the tail of the arrow results in display of RNA aptamer or folate on the outer surface of the extracellular vesicle. In contrast, placing the cholesterol at the arrowhead results in partial loading of RNA nanoparticles into the extracellular vesicles. Taking advantage of the RNA ligand for specific targeting and extracellular vesicles for efficient membrane fusion, the resulting ligand-displaying extracellular vesicles were capable of specific delivery of siRNA to cells, and efficiently blocked tumour growth in three cancer models. Extracellular vesicles displaying an aptamer that binds to prostate-specific membrane antigen, and loaded with survivin siRNA, inhibited prostate cancer xenograft. The same extracellular vesicle instead displaying epidermal growth-factor receptor aptamer inhibited orthotopic breast cancer models. Likewise, survivin siRNA-loaded and folate-displaying extracellular vesicles inhibited patient-derived colorectal cancer xenograft.RNA nanotechnology is utilized for directional control by altering the orientation of arrow-shaped RNAs for either ligand-display on extracellular vesicle or to regulate intracellular trafficking of siRNA or miRNA in cancer treatment.

[1]  P. Low,et al.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. , 2005, Analytical biochemistry.

[2]  Steven M Jay,et al.  Exogenous DNA Loading into Extracellular Vesicles via Electroporation is Size-Dependent and Enables Limited Gene Delivery. , 2015, Molecular pharmaceutics.

[3]  J. Leonard,et al.  FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver , 2013, Pharmaceuticals.

[4]  George A. Calin,et al.  RNA interference in the clinic: challenges and future directions , 2011, Nature Reviews Cancer.

[5]  Shinobu Ueda,et al.  Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  Gert Storm,et al.  Endosomal escape pathways for delivery of biologicals. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[7]  P. Guo,et al.  A small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNA. , 1987, Science.

[8]  Yong Song Gho,et al.  Importance of exosome depletion protocols to eliminate functional and RNA-containing extracellular vesicles from fetal bovine serum , 2014, Journal of extracellular vesicles.

[9]  Jian Song,et al.  A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. , 2014, Biomaterials.

[10]  Peixuan Guo,et al.  Thermodynamically Stable RNA three-way junctions as platform for constructing multi-functional nanoparticles for delivery of therapeutics , 2011, Nature Nanotechnology.

[11]  Peixuan Guo,et al.  Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. , 2012, Nano today.

[12]  C. Croce,et al.  RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model , 2015, Oncotarget.

[13]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[14]  N. Bander,et al.  In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen , 2002, Prostate Cancer and Prostatic Diseases.

[15]  Peixuan Guo,et al.  Large scale purification of RNA nanoparticles by preparative ultracentrifugation. , 2015, Methods in molecular biology.

[16]  R. Schiff,et al.  Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes , 2010, Cancer.

[17]  Aled Clayton,et al.  Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids , 2006, Current protocols in cell biology.

[18]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[19]  Mike Wilson,et al.  Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Brian C Evans,et al.  Mechanism of Enhanced Cellular Uptake and Cytosolic Retention of MK2 Inhibitory Peptide Nano-polyplexes , 2016, Cellular and molecular bioengineering.

[21]  Gerolama Condorelli,et al.  A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death , 2011, PloS one.

[22]  Imre Mäger,et al.  Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting , 2015, Journal of extracellular vesicles.

[23]  F. Höök,et al.  Bivalent cholesterol-based coupling of oligonucletides to lipid membrane assemblies. , 2004, Journal of the American Chemical Society.

[24]  M. Daidone,et al.  Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells , 2006, Molecular Cancer Therapeutics.

[25]  D. Pegtel,et al.  Extracellular Vesicles Exploit Viral Entry Routes for Cargo Delivery , 2016, Microbiology and Molecular Reviews.

[26]  R. Schiffelers,et al.  Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[27]  C. Zhang,et al.  Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation. , 1998, Molecular cell.

[28]  W. M. Rockey,et al.  Targeted Inhibition of Prostate Cancer Metastases with an RNA Aptamer to Prostate-specific Membrane Antigen , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  S. Shankar,et al.  Biomolecular characterization of exosomes released from cancer stem cells: Possible implications for biomarker and treatment of cancer , 2014, Oncotarget.

[30]  A. Herrmann,et al.  Lipid membranes carrying lipophilic cholesterol-based oligonucleotides--characterization and application on layer-by-layer coated particles. , 2009, The journal of physical chemistry. B.

[31]  Peixuan Guo.  The emerging field of RNA nanotechnology. , 2010, Nature nanotechnology.

[32]  Peixuan Guo,et al.  Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. , 2005, Nano letters.

[33]  Christian Pilarsky,et al.  Glypican-1 identifies cancer exosomes and detects early pancreatic cancer , 2015, Nature.

[34]  Peixuan Guo,et al.  Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying both Ligand and siRNA , 2015, Scientific Reports.

[35]  Y. Lyubchenko,et al.  Crystal structure of 3WJ core revealing divalent ion-promoted thermostability and assembly of the Phi29 hexameric motor pRNA , 2013, RNA.

[36]  G. Xiong,et al.  Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology , 2015, ACS nano.

[37]  Emil F. Khisamutdinov,et al.  Programmable folding of fusion RNA in vivo and in vitro driven by pRNA 3WJ motif of phi29 DNA packaging motor , 2013, Nucleic acids research.

[38]  J. McNamara,et al.  Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. , 2011, Nucleic acid therapeutics.

[39]  J. Rak.  Cancer: Organ-seeking vesicles , 2015, Nature.

[40]  Michelle E. Hung,et al.  Stabilization of Exosome-targeting Peptides via Engineered Glycosylation* , 2015, The Journal of Biological Chemistry.

[41]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[42]  Imre Mäger,et al.  Extracellular vesicles: biology and emerging therapeutic opportunities , 2013, Nature Reviews Drug Discovery.

[43]  M. Wood,et al.  Exosomes for targeted siRNA delivery across biological barriers. , 2013, Advanced drug delivery reviews.

[44]  Peixuan Guo,et al.  Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  Lynne T. Bemis,et al.  Standardization of sample collection, isolation and analysis methods in extracellular vesicle research , 2013, Journal of extracellular vesicles.